Recruiting

Observational Study

Sponsor:

University of Central Florida

Code:

NCT06148298

Conditions

Cancer of Pancreas

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Non-Human Subject Research study.

Study Details

Brief summary:

The goal of this research is to use chromatin immunoprecipitation, a method used to study protein-DNA interaction, as a tool to diagnose and prognose pancreatic ductal adenocarcinoma in human samples.

This is a Non-Human Subject Research study. All participants are de-identified.

Conditions

Cancer of Pancreas

Study ID

NCT06148298

Start date

May 24, 2023

Status verified date

Dec, 2024

Completion date

May, 2025

Anticipated

Primary completion date

May, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • 18 years old or older
  • Pancreatic cancer patients

Exclusion Criteria:

  • Children may not register
  • Persons who are unable to consent may not register

Study Design

Enrollment

24 participants

Anticipated

Interventions and Outcome Measures

Arms

Pancreatic Ductal Adenocarcinoma

Interventions

Non-Human Subject Research study.

This is a Non-Human Subject Research study. There is no intervention. All participants are de-identified.

Primary outcome measure

  • Level of c-ERBB1 in blood using Chromatin immunoprecipitation and Reverse transcription-quantitative polymerase chain reaction [ Time Frame: 1 year ]

Central Contacts and Locations

Central contacts

Amoy Fraser, PhD, CCRP, PMP

4072668742amoy.fraser@ucf.edu

Erica Martin, B.S.

4072668742erica.martin@ucf.edu

Locations

University of Central Florida

Recruiting

Orlando, Florida, United States, 32816

More Information

Sponsor

University of Central Florida

Last update posted

Dec 6, 2024

Last verified

Dec, 2024

Keywords

  • cancer
  • pancreas

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Central Florida on 2024-12-06.